Intrinsic value of DexCom - DXCM

Previous Close

$99.45

  Intrinsic Value

$19.40

stock screener

  Rating & Target

str. sell

-80%

Previous close

$99.45

 
Intrinsic value

$19.40

 
Up/down potential

-80%

 
Rating

str. sell

We calculate the intrinsic value of DXCM stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 8.6

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  25.30
  23.27
  21.44
  19.80
  18.32
  16.99
  15.79
  14.71
  13.74
  12.86
  12.08
  11.37
  10.73
  10.16
  9.64
  9.18
  8.76
  8.39
  8.05
  7.74
  7.47
  7.22
  7.00
  6.80
  6.62
  6.46
  6.31
  6.18
  6.06
  5.96
Revenue, $m
  901
  1,111
  1,349
  1,616
  1,912
  2,236
  2,590
  2,970
  3,379
  3,813
  4,274
  4,760
  5,270
  5,806
  6,366
  6,950
  7,559
  8,193
  8,852
  9,538
  10,250
  10,990
  11,759
  12,559
  13,390
  14,255
  15,155
  16,091
  17,067
  18,083
Variable operating expenses, $m
  768
  947
  1,149
  1,377
  1,629
  1,905
  2,206
  2,530
  2,877
  3,247
  3,638
  4,052
  4,487
  4,943
  5,419
  5,917
  6,435
  6,975
  7,536
  8,120
  8,726
  9,356
  10,011
  10,692
  11,400
  12,136
  12,902
  13,699
  14,529
  15,395
Fixed operating expenses, $m
  154
  158
  161
  165
  168
  172
  176
  180
  184
  188
  192
  196
  200
  205
  209
  214
  219
  223
  228
  233
  238
  244
  249
  255
  260
  266
  272
  278
  284
  290
Total operating expenses, $m
  922
  1,105
  1,310
  1,542
  1,797
  2,077
  2,382
  2,710
  3,061
  3,435
  3,830
  4,248
  4,687
  5,148
  5,628
  6,131
  6,654
  7,198
  7,764
  8,353
  8,964
  9,600
  10,260
  10,947
  11,660
  12,402
  13,174
  13,977
  14,813
  15,685
Operating income, $m
  -22
  6
  38
  74
  115
  159
  208
  261
  317
  378
  444
  512
  583
  658
  737
  819
  905
  995
  1,088
  1,185
  1,285
  1,390
  1,499
  1,613
  1,731
  1,853
  1,981
  2,115
  2,253
  2,398
EBITDA, $m
  -3
  29
  65
  107
  153
  204
  259
  320
  384
  453
  526
  604
  685
  771
  861
  954
  1,052
  1,154
  1,259
  1,370
  1,484
  1,603
  1,727
  1,856
  1,990
  2,130
  2,275
  2,427
  2,585
  2,749
Interest expense (income), $m
  0
  26
  31
  41
  53
  66
  80
  96
  113
  131
  151
  172
  194
  218
  242
  268
  295
  324
  353
  384
  415
  449
  483
  519
  556
  594
  635
  676
  720
  765
  812
Earnings before tax, $m
  -47
  -25
  -3
  21
  49
  79
  112
  148
  186
  227
  272
  317
  366
  416
  469
  524
  582
  642
  704
  769
  837
  907
  980
  1,057
  1,136
  1,219
  1,305
  1,395
  1,488
  1,586
Tax expense, $m
  0
  0
  0
  6
  13
  21
  30
  40
  50
  61
  73
  86
  99
  112
  127
  142
  157
  173
  190
  208
  226
  245
  265
  285
  307
  329
  352
  377
  402
  428
Net income, $m
  -47
  -25
  -3
  16
  36
  58
  82
  108
  136
  166
  198
  232
  267
  304
  342
  383
  425
  468
  514
  562
  611
  662
  716
  771
  829
  890
  953
  1,018
  1,086
  1,158

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  620
  764
  928
  1,112
  1,316
  1,539
  1,782
  2,044
  2,325
  2,624
  2,941
  3,276
  3,627
  3,996
  4,381
  4,783
  5,202
  5,639
  6,092
  6,564
  7,054
  7,564
  8,093
  8,643
  9,216
  9,811
  10,430
  11,075
  11,746
  12,446
Adjusted assets (=assets-cash), $m
  620
  764
  928
  1,112
  1,316
  1,539
  1,782
  2,044
  2,325
  2,624
  2,941
  3,276
  3,627
  3,996
  4,381
  4,783
  5,202
  5,639
  6,092
  6,564
  7,054
  7,564
  8,093
  8,643
  9,216
  9,811
  10,430
  11,075
  11,746
  12,446
Revenue / Adjusted assets
  1.453
  1.454
  1.454
  1.453
  1.453
  1.453
  1.453
  1.453
  1.453
  1.453
  1.453
  1.453
  1.453
  1.453
  1.453
  1.453
  1.453
  1.453
  1.453
  1.453
  1.453
  1.453
  1.453
  1.453
  1.453
  1.453
  1.453
  1.453
  1.453
  1.453
Average production assets, $m
  175
  215
  262
  313
  371
  434
  502
  576
  655
  740
  829
  923
  1,022
  1,126
  1,235
  1,348
  1,466
  1,589
  1,717
  1,850
  1,989
  2,132
  2,281
  2,436
  2,598
  2,765
  2,940
  3,122
  3,311
  3,508
Working capital, $m
  -52
  -64
  -78
  -94
  -111
  -130
  -150
  -172
  -196
  -221
  -248
  -276
  -306
  -337
  -369
  -403
  -438
  -475
  -513
  -553
  -595
  -637
  -682
  -728
  -777
  -827
  -879
  -933
  -990
  -1,049
Total debt, $m
  401
  530
  678
  843
  1,027
  1,228
  1,446
  1,682
  1,935
  2,204
  2,490
  2,791
  3,107
  3,439
  3,786
  4,148
  4,525
  4,917
  5,326
  5,750
  6,191
  6,650
  7,126
  7,622
  8,137
  8,672
  9,229
  9,810
  10,414
  11,043
Total liabilities, $m
  558
  688
  835
  1,001
  1,184
  1,385
  1,604
  1,840
  2,093
  2,362
  2,647
  2,948
  3,265
  3,596
  3,943
  4,305
  4,682
  5,075
  5,483
  5,908
  6,349
  6,807
  7,284
  7,779
  8,294
  8,830
  9,387
  9,967
  10,571
  11,201
Total equity, $m
  62
  76
  93
  111
  132
  154
  178
  204
  233
  262
  294
  328
  363
  400
  438
  478
  520
  564
  609
  656
  705
  756
  809
  864
  922
  981
  1,043
  1,107
  1,175
  1,245
Total liabilities and equity, $m
  620
  764
  928
  1,112
  1,316
  1,539
  1,782
  2,044
  2,326
  2,624
  2,941
  3,276
  3,628
  3,996
  4,381
  4,783
  5,202
  5,639
  6,092
  6,564
  7,054
  7,563
  8,093
  8,643
  9,216
  9,811
  10,430
  11,074
  11,746
  12,446
Debt-to-equity ratio
  6.460
  6.940
  7.300
  7.580
  7.800
  7.980
  8.120
  8.230
  8.320
  8.400
  8.460
  8.520
  8.570
  8.610
  8.640
  8.670
  8.700
  8.720
  8.740
  8.760
  8.780
  8.790
  8.810
  8.820
  8.830
  8.840
  8.850
  8.860
  8.870
  8.870
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -47
  -25
  -3
  16
  36
  58
  82
  108
  136
  166
  198
  232
  267
  304
  342
  383
  425
  468
  514
  562
  611
  662
  716
  771
  829
  890
  953
  1,018
  1,086
  1,158
Depreciation, amort., depletion, $m
  19
  23
  27
  33
  38
  45
  51
  59
  67
  75
  83
  92
  102
  113
  123
  135
  147
  159
  172
  185
  199
  213
  228
  244
  260
  277
  294
  312
  331
  351
Funds from operations, $m
  -28
  -2
  24
  48
  74
  102
  133
  167
  203
  241
  281
  324
  369
  416
  466
  517
  571
  627
  686
  747
  810
  876
  944
  1,015
  1,089
  1,166
  1,247
  1,330
  1,418
  1,509
Change in working capital, $m
  -11
  -12
  -14
  -15
  -17
  -19
  -20
  -22
  -24
  -25
  -27
  -28
  -30
  -31
  -32
  -34
  -35
  -37
  -38
  -40
  -41
  -43
  -45
  -46
  -48
  -50
  -52
  -54
  -57
  -59
Cash from operations, $m
  -18
  10
  38
  64
  91
  121
  154
  189
  226
  266
  308
  352
  399
  447
  498
  551
  607
  664
  724
  786
  851
  918
  989
  1,061
  1,137
  1,216
  1,299
  1,385
  1,474
  1,568
Maintenance CAPEX, $m
  -14
  -17
  -22
  -26
  -31
  -37
  -43
  -50
  -58
  -66
  -74
  -83
  -92
  -102
  -113
  -123
  -135
  -147
  -159
  -172
  -185
  -199
  -213
  -228
  -244
  -260
  -277
  -294
  -312
  -331
New CAPEX, $m
  -36
  -41
  -46
  -52
  -57
  -63
  -68
  -74
  -79
  -84
  -89
  -94
  -99
  -104
  -109
  -113
  -118
  -123
  -128
  -133
  -138
  -144
  -149
  -155
  -161
  -168
  -175
  -182
  -189
  -197
Cash from investing activities, $m
  -50
  -58
  -68
  -78
  -88
  -100
  -111
  -124
  -137
  -150
  -163
  -177
  -191
  -206
  -222
  -236
  -253
  -270
  -287
  -305
  -323
  -343
  -362
  -383
  -405
  -428
  -452
  -476
  -501
  -528
Free cash flow, $m
  -67
  -48
  -30
  -14
  2
  21
  42
  65
  90
  116
  145
  175
  207
  241
  277
  314
  354
  395
  437
  482
  528
  576
  626
  678
  732
  789
  848
  909
  973
  1,039
Issuance/(repayment) of debt, $m
  73
  130
  148
  165
  183
  201
  219
  236
  253
  269
  285
  301
  316
  332
  347
  362
  377
  393
  408
  425
  441
  458
  476
  495
  515
  536
  557
  580
  604
  630
Issuance/(repurchase) of shares, $m
  100
  39
  20
  3
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  173
  169
  168
  168
  183
  201
  219
  236
  253
  269
  285
  301
  316
  332
  347
  362
  377
  393
  408
  425
  441
  458
  476
  495
  515
  536
  557
  580
  604
  630
Total cash flow (excl. dividends), $m
  105
  121
  137
  154
  186
  222
  261
  301
  342
  385
  430
  476
  524
  573
  624
  676
  731
  787
  846
  906
  969
  1,034
  1,103
  1,173
  1,247
  1,324
  1,405
  1,489
  1,577
  1,669
Retained Cash Flow (-), $m
  -100
  -39
  -20
  -18
  -20
  -22
  -24
  -26
  -28
  -30
  -32
  -33
  -35
  -37
  -39
  -40
  -42
  -44
  -45
  -47
  -49
  -51
  -53
  -55
  -57
  -60
  -62
  -64
  -67
  -70
Prev. year cash balance distribution, $m
  410
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  106
  133
  164
  200
  239
  283
  331
  383
  440
  500
  564
  633
  704
  780
  859
  942
  1,029
  1,119
  1,213
  1,310
  1,412
  1,517
  1,627
  1,740
  1,859
  1,982
  2,110
  2,243
  2,382
  2,526
Cash available for distribution, $m
  415
  82
  118
  135
  165
  200
  236
  274
  314
  356
  398
  443
  489
  536
  585
  636
  689
  744
  800
  859
  920
  984
  1,050
  1,118
  1,190
  1,265
  1,343
  1,425
  1,510
  1,599
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  398
  75
  102
  112
  128
  145
  160
  172
  181
  186
  189
  189
  186
  180
  172
  162
  150
  137
  123
  109
  95
  82
  69
  57
  46
  37
  29
  22
  16
  12
Current shareholders' claim on cash, %
  48.2
  45.3
  44.2
  44.1
  44.1
  44.1
  44.1
  44.1
  44.1
  44.1
  44.1
  44.1
  44.1
  44.1
  44.1
  44.1
  44.1
  44.1
  44.1
  44.1
  44.1
  44.1
  44.1
  44.1
  44.1
  44.1
  44.1
  44.1
  44.1
  44.1

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

FINANCIAL RATIOS  of  DexCom (DXCM)

Valuation Ratios
P/E Ratio -127.5
Price to Sales 14.7
Price to Book 29.6
Price to Tangible Book
Price to Cash Flow 150.2
Price to Free Cash Flow 0
Growth Rates
Sales Growth Rate 42.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 69.7%
Cap. Spend. - 3 Yr. Gr. Rate 47.6%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -19%
Ret/ On Assets - 3 Yr. Avg. -19.2%
Return On Total Capital -26%
Ret/ On T. Cap. - 3 Yr. Avg. -25.4%
Return On Equity -26.1%
Return On Equity - 3 Yr. Avg. -26%
Asset Turnover 1.6
Profitability Ratios
Gross Margin 66%
Gross Margin - 3 Yr. Avg. 67.7%
EBITDA Margin -8.7%
EBITDA Margin - 3 Yr. Avg. -8.6%
Operating Margin -11.2%
Oper. Margin - 3 Yr. Avg. -11.3%
Pre-Tax Margin -11.3%
Pre-Tax Margin - 3 Yr. Avg. -11.4%
Net Profit Margin -11.5%
Net Profit Margin - 3 Yr. Avg. -11.5%
Effective Tax Rate -1.5%
Eff/ Tax Rate - 3 Yr. Avg. -0.5%
Payout Ratio 0%

DXCM stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the DXCM stock intrinsic value calculation we used $719 million for the last fiscal year's total revenue generated by DexCom. The default revenue input number comes from 2017 income statement of DexCom. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our DXCM stock valuation model: a) initial revenue growth rate of 25.3% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for DXCM is calculated based on our internal credit rating of DexCom, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of DexCom.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of DXCM stock the variable cost ratio is equal to 85.3%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $151 million in the base year in the intrinsic value calculation for DXCM stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 7.8% for DexCom.

Corporate tax rate of 27% is the nominal tax rate for DexCom. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the DXCM stock is equal to 14.8%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for DXCM are equal to 19.4%.

Life of production assets of 10 years is the average useful life of capital assets used in DexCom operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for DXCM is equal to -5.8%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $419 million for DexCom - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 86 million for DexCom is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of DexCom at the current share price and the inputted number of shares is $8.6 billion.

RELATED COMPANIES Price Int.Val. Rating
SENS Senseonics Hol 4.00 0.02  str.sell
JNJ Johnson&Johnso 124.69 126.96  hold
ABT Abbott Laborat 61.78 80.26  buy
DRIO DarioHealth 1.38 0.10  str.sell
WST West Pharmaceu 98.45 34.77  str.sell
CAH Cardinal Healt 50.71 169.21  str.buy

COMPANY NEWS

▶ Top Analysts Say Gamble On These 3 Ace Stocks   [Jul-16-18 09:30AM  TheStreet.com]
▶ 3 Top Growth Stocks to Buy in July   [Jul-11-18 08:30AM  Motley Fool]
▶ Top Stocks Set to Disrupt the Diabetes Market   [Jul-06-18 12:59PM  Motley Fool]
▶ 3 Best Diabetes Stocks of 2018 So Far   [06:34AM  Motley Fool]
▶ Big News Sends Tandem Diabetes Soaring 10.2% Today   [Jun-22-18 12:59PM  Motley Fool]
▶ Dexcom plans 300 hires this year, including 100 this week   [Jun-20-18 04:22PM  American City Business Journals]
▶ DexCom Stock History   [Jun-13-18 07:24PM  Motley Fool]
▶ Dexcom G6® CGM System Receives CE Mark   [Jun-12-18 07:00AM  Business Wire]
▶ Portland-area medical device maker wins another round in federal court   [Jun-04-18 09:22AM  American City Business Journals]
▶ 3 Top Stocks That Aren't on Wall Street's Radar   [May-25-18 03:57PM  Motley Fool]
▶ Five Top MedTech Stocks in Diabetes   [12:40PM  Motley Fool]
▶ DexCom Announces Upcoming Conference Presentation   [May-17-18 08:00AM  Business Wire]
▶ Here's Why DexCom Is Surging Today   [10:49AM  Motley Fool]
▶ DexCom: 1Q Earnings Snapshot   [May-02-18 05:33PM  Associated Press]
▶ Edited Transcript of DXCM presentation 6-Mar-17 9:00pm GMT   [Apr-10-18 04:58PM  Thomson Reuters StreetEvents]
▶ Here's Why Senseonics Holdings Inc. Is Rising Today   [Apr-04-18 03:35PM  Motley Fool]
▶ DexCom reports 4Q loss   [Feb-27-18 05:31PM  Associated Press]
▶ DexCom, Inc. to Host Earnings Call   [12:50PM  ACCESSWIRE]
▶ DexCom Q4 Earnings Preview   [12:29PM  Benzinga]
▶ DexCom Announces Upcoming Conference Presentations   [Feb-12-18 08:00AM  Business Wire]
▶ Fitbit for Kids? FIT Considering Smartwatch for Children   [Jan-09-18 01:12PM  InvestorPlace]
▶ 4 MedTech Stocks to Explode in 2018   [Dec-22-17 02:33PM  Zacks]
▶ DexCom Announces Upcoming Conference Presentation   [Dec-12-17 08:00AM  Business Wire]
▶ ETFs with exposure to DexCom, Inc. : December 8, 2017   [Dec-08-17 12:42PM  Capital Cube]
▶ ETFs with exposure to DexCom, Inc. : November 27, 2017   [Nov-27-17 01:13PM  Capital Cube]
▶ 3 Top Medical Device Stocks to Buy Now   [Nov-18-17 11:32AM  Motley Fool]
▶ ETFs with exposure to DexCom, Inc. : November 17, 2017   [Nov-17-17 11:44AM  Capital Cube]
▶ DexCom Announces Upcoming Conference Presentation   [Nov-09-17 08:00AM  Business Wire]
▶ ETFs with exposure to DexCom, Inc. : November 6, 2017   [Nov-06-17 11:28AM  Capital Cube]
▶ Why Fitbit Inc Stock Can Climb Back Out of Its Grave   [Nov-02-17 12:04PM  InvestorPlace]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.